Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
Aims: Aim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs. Aim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
View:
• Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.
Locations
United States
Missouri
Barnes Jewish Hospital
RECRUITING
St Louis
Washington Univeristy
RECRUITING
St Louis
Contact Information
Primary
Tracey Bach, MBA
habrockt@wustl.edu
314-273-6075
Backup
Laura Marks, MD, PhD
marks@wustl.edu
Time Frame
Start Date: 2024-02-01
Estimated Completion Date: 2026-02-28
Participants
Target number of participants: 50
Treatments
Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c
Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.
Related Therapeutic Areas
Sponsors
Leads: Washington University School of Medicine